Q J Med 1994; 87: 283-290
© 1994 Association of Physicians
research-article |
Helicobacter pylori eradication in patients with peptic ulcer disease: clinical consequences and financial implications
1Departments of Medicine The Ipswich Hospital Ipswich, UK 2Departments of Medical Physics The Ipswich Hospital Ipswich, UK 3Departments of Histopathology The Ipswich Hospital Ipswich, UK 4Departments of Regional Drug Information Unit The Ipswich Hospital Ipswich, UK 5Departments of the PHLS The Ipswich Hospital Ipswich, UK 6Departments of Suffolk Medical Audit Advisory Group Facilitator The Ipswich Hospital Ipswich, UK 7Departments of Audit Office, The Ipswich Hospital Ipswich, UK
Address correspondence to Dr G.D. Bell, Department of Medicine, The Ipswich Hospital, Ipswich, Suffolk IP4 5PD
Received 24 January 1994 Accepted for publication 8 February 1994.
We assessed clinical consequences and financial implications of Helicobacter pylori eradication in 175 patients with peptic ulceration, of whom 106 had been free from H. pylori infection for a mean of 3.2 years, while 69 remained infected. We used quarterly questionnaires to examine consumption of ulcer-healing medication and antacids. In the 106 successfully treated patients, gastrointestinal haemorrhage as a complication of peptic ulcer complications during the 344 patient years after eradication (0.003 per patient year) was 18-fold lower than during the 912 patient years before eradication (0.056 per patient year). Of the H. pylori-negative patients, 1218% used ulcer-healing medication during any one of the three-month periods of the survey, compared with 3451 % of the patients with residual H. pylori infection. The average cost of the ulcer-healing drugs consumed by the H. pylori-negative patients was £30.59 during the 12 months of the survey, compared with £99.05 for H. pylori-positive patients. Consumption of antacids was also lower in the H. pylori-negative group. Successful eradication of H. pylori significantly reduced the annual cost of ulcer-healing drugs consumed by the patients with ulcer disease. Maintenance of ulcer remission following successful eradication of H. pylori also significantly reduced ulcer complications.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. LABENZ and P. MALFERTHEINER Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor? Gut, September 1, 1997; 41(3): 277 - 280. [Full Text] [PDF] |
||||
![]() |
P S Phull and M R Jacyna Testing to check success of treatment to eradicate H pylori BMJ, September 21, 1996; 313(7059): 752a - 752. [Full Text] |
||||
![]() |
T G Reilly and R P Walt Routine retesting is necessary BMJ, May 25, 1996; 312(7042): 1362 - 1362. [Full Text] |
||||
![]() |
K Bodger and R V Heatley Testing to check success of treatment to eradicate H pylori BMJ, May 25, 1996; 312(7042): 1361b - 1362. [Full Text] |
||||
![]() |
T Walley Upper gastrointestinal endoscopy BMJ, July 1, 1995; 311(6996): 57c - 58. [Full Text] |
||||

